4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Pulmonary Arterial Hypertension by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 742 ongoing clinical trials involving Pulmonary Arterial Hypertension
Of the 742 trials,411 trials are in Phase III
Furthermore, 163 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Pulmonary Arterial Hypertension by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Pulmonary Arterial Hypertension, a cardiovascular indication. The largest number of ongoing clinical trials for Pulmonary Arterial Hypertension is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Pulmonary Arterial Hypertension-related drug trials.

Actelion Pharmaceuticals Ltd: The leading ongoing Pulmonary Arterial Hypertension related clinical trial sponsor

Actelion Pharmaceuticals Ltd is the top sponsor for Pulmonary Arterial Hypertension-related ongoing clinical trials.

Acceleron Pharma Inc, United Therapeutics Corp, Bayer AG, and Vanderbilt University Medical Center are among other notable clinical trial sponsors involved in Pulmonary Arterial Hypertension. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pulmonary Arterial Hypertension

Macitentan (ACT-064992, Opsumit, Zependo), Selexipag (Uptravi), and Riociguat (Adempas) are among the key marketed drugs involving Pulmonary Arterial Hypertension.

Macitentan (ACT-064992, Opsumit, Zependo) is a novel dual endothelin receptor antagonist (ERA). It functions via Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Antagonist; Endothelin B Receptor (Endothelin Receptor Non-Selective Type or EDNRB) Antagonist mechanism of action. It is formulated as film coated tablets for the oral route of administration. Macitentan is marketed for the treatment of Pulmonary Arterial Hypertension and several other indications including Glioblastoma Multiforme (GBM), Congenital Heart Disease, Idiopathic Pulmonary Fibrosis, Diastolic Heart Failure, Chronic Thromboembolic Pulmonary Hypertension, Digital Ulcers, Eisenmenger Syndrome, Pulmonary Hypertension, and Pulmonary Vascular Disease (PVD). Macitentan was first approved in 2013 and is marketed globally including the US, the UK, France, and Australia by Janssen Inc, Handok Inc, and Actelion Pharmaceuticals Ltd.

Selexipag (Uptravi) is an antithrombotic agent. It functions via Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) Agonist mechanism of action. It is formulated as film coated tablets for oral route of administration and powder for solution for intravenous route of administration. Uptravi is indicated for the treatment of pulmonary arterial hypertension to delay disease progression and reduce the risk of hospitalization. Uptravi is also indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. Selexipag was first approved in 2015 and is marketed globally including the US, the UK, France, and Australia by Janssen-Cilag Pharma GmbH, and Actelion Pharmaceuticals Ltd.